Perosphere Technologies, a developer of next-generation coagulation diagnostics, has signed an exclusive agreement with CoRRect Medical for the distribution of its point-of-care (PoC) coagulometer in Germany.

Perosphere's PoC coagulometer is a reagent-free, pharmacodynamic diagnostic instrument. It aims to facilitate rapid coagulation status diagnosis and support informed treatment decisions for patients on anticoagulant therapies, including direct oral anticoagulants (DOACs).

Its deployment at the bedside or in outpatient clinics is expected to enhance medical management in various hospital settings.

Perosphere chief operating officer Daryl Mootoo said: “We are eager to partner with CoRRect Medical to introduce Perosphere’s PoC coagulometer in Germany, addressing the unmet medical need in coagulation testing and management to help improve patient outcomes and reduce associated costs.

“CoRRect Medical has outstanding expertise in understanding the needs of healthcare professionals to provide solutions that can integrate seamlessly into practice.”

The PoC coagulometer, distributed through CoRRect Medical, is expected to meet the growing need for advanced coagulation diagnostics within Germany's healthcare system.

Perosphere also holds an exclusive agreement with M3 Medical, another Uniphar Medtech business, for the distribution of the PoC coagulometer in Ireland.

CoRRect Medical CEO Michael Braun said: “We are inspired by Perosphere’s medical innovation and proud to be entrusted as its exclusive partner to bring this point-of-care, DOAC-sensitive coagulation testing device to the health system in Germany.

“The PoC coagulometer will fill a critical diagnostic void for healthcare professionals and help improve care outcomes for patients.”

Part of the Uniphar Medtech Group, CoRRect Medical is engaged in the commercialisation and distribution of medical devices in cardiology, vascular surgery, and cardiac surgery across Europe.